Tag: car t cell therapy companies

The “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 report features an extensive study of the current market landscape and future potential of CAR-T therapies over the next decade. Key Inclusions A detailed assessment of the current market landscape of  CAR-T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastr...

CAR-T cell therapies have been shown to enable complete disease remission, omitting the need for any further treatment. Several studies have proven the efficacy of these therapy candidates. Driven by the ongoing pace of innovation and sufficient financial support from investors, the CAR-T cell therapy market is anticipated to witness substantial growth in the foreseen future The financial opportunity within the CAR T cell therapy market has been analyzed across the following segments: Target Indication(s) Non-Hodgkin’s Lymphoma Multiple Myeloma Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Hodgkin’s Lymphoma Acute Myeloid Leukemia Ovarian Cancer Generalized Myasthenia Gravis (MG) Renal Cell Carcinoma Target Antigen CD19 BCMA C...